Wire · regulatory
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for PSMA+ mHSPC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 August 2026 · Fusion42 review
The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an androgen receptor pathway inhibitor for treatment of PSMA-positive metastatic hormone-sensitive prostate cancer, based on phase 3 trial data demonstrating reduced progression risk and potential overall survival benefits.
This Wire brief sits within Fusion42's coverage of Biotech, and 1 source has reported it between 1 Aug 2026 and 13 Aug 2026.
◆ ◆ The Wire takeaway
You must now include PSMA-targeted radioligand therapy in your prostate cancer treatment strategy, as FDA approval expands early treatment options and raises the standard of care. This opens a new competitive front where firms offering advanced diagnostics or combination therapies can move fast.
◆ Coverage
1 source · first reported 1 Aug 2026 · latest 13 Aug 2026
◆ Related on Wire
◆ Topics